Navigation Links
Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Date:10/22/2008

COLUMBUS, Ohio, Oct. 22 /PRNewswire/ -- Last week, Roxane Laboratories, Inc. launched its calcium acetate capsules, 667mg. Since the October 15 exclusive launch of this product, Roxane Laboratories, Inc., has experienced tremendous demand.

Roxane Laboratories' calcium acetate capsules, 667mg are the only AB rated generic alternative to PhosLo(R) (calcium acetate) capsules, used in the treatment of high levels of phosphate in patients with chronic renal failure. Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8 million(1).

Full prescribing information for calcium acetate capsules, 667mg is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information hotline at 1-800-962-8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,8
'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
8. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
9. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
10. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... in its catalogue: Acute Heart Failure ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart ... Summary GlobalData,s clinical trial report, "Acute ... provides data on the Acute Heart Failure clinical ...
(Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 12, 2009, at ... operating performance for the first quarter ended September 30, ... and marketing activities. , Corgenix invites all those interested ...
... 3 On-Q-ity, a next-generation oncology diagnostics company ... that it has closed a $21 million series ... MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, ... http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO ) , On-Q-ity is developing ...
Cached Medicine Technology:Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:9/2/2014)... 2014 (HealthDay News) -- Complications are rare among ... a new study indicates. However, the researchers ... with a slightly higher risk for certain complications ... more than 18,000 breast cancer patients who had ... with breast reconstruction and were followed for 30 ...
(Date:9/2/2014)... can lay the groundwork for their own spread throughout ... send out tumor-welcoming signals, according to a new report ... 2 issue of Nature Communications , the researchers ... of so-called signaling molecules released by breast cancer cells. ... lungs and lymph nodes to produce proteins called CCL5 ...
(Date:9/2/2014)... Operators in the Community Services industry ... arranging care and counsel for those in need. In ... to derive $39.4 billion in revenue, which includes a ... the five years through 2014-15, the subdivision is forecast ... growth of 4.1% in 2014-15. , As the population ...
(Date:9/2/2014)... Melatonin supplements did not reduce delirium in seniors who ... Many older hospital patients experience the sudden, severe ... normal sleep-wake cycle. A lack of the hormone melatonin ... there has been little research into whether melatonin supplements ... patients, average age 84, who had hip fracture surgery. ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, ... outbreak continues to overwhelm health-care workers in three West ... the United Nations called on Tuesday for a concerted ... often-fatal virus. Dr. Thomas Frieden, director of the ... without a greater global commitment in resources -- both ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... depression resulting form multiple sclerosis had showed marked ... // The results of the investigation were reported ... Psychiatry. ,Although two-thirds of depressed patients prefer ... ever make a first appointment and nearly half ...
... the spread of gastrointestinal infections in the home. // ... families, which used the hand sanitizer in gel form, ... illness related to the gastrointestinal tract. ,Families ... Half the families were randomly assigned to receive hand ...
... high regard since the very old days and it continues ... recreation forms have been able to substitute mankind with another ... sudden death associated with exercise in young competitors. The benefits ... ,Recent medical research has reported that adolescents and ...
... elevate the role of fibres further by stating that ... plaque build-up in the arteries in postmenopausal women.// ... with a decreased risk of heart disease and death. ... fruit, and vegetables, and refined grain products on the ...
... said that the government would include Hepatitis B ... has been emerging as a "problem greater than ... Indian Council of Medical Research (ICMR)-World Health Organisation ... leptospirosis at the regional ICMR centre here, the ...
... Manoor Prakash Hande and his colleagues from National University ... risk of developing Chromosomal aberrations leading to cancer// in ... aimed at identifying biomarkers for easy detection and identification ... finding a link between complex chromosome aberrations and disease ...
Cached Medicine News:Health News:MS Patients Improve With Telephone Therapy 2Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Competitive Sports: Is the heart Sportive Enough? 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: